The DOI matches its Crossref record.
Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis
Abstract
Interferon gamma (IFN-γ) inhibits in vitro the activation of hepatic stellate cells (HSC), the primary extracellular matrix-producing cells in liver fibrosis. This study was undertaken to determine in vivo the effect of IFN-γ in the rat model of liver fibrosis induced by dimethylnitrosamine (DMN), where HSC activation represents an early response to cell injury. Rats were killed after 1 or 3 weeks of treatment with DMN, IFN-γ, DMN + IFN-γ, or saline. Immunohistochemistry was used to identify proliferating (desmin- positive/bromodeoxyuridine (BrdU)-positive cells) and activated (α- smooth-muscle actin [α-SMA]-positive cells) HSCs. Collagen deposition was determined colorimetrically and by morphometry. The parenchymal extension of desmin- and actin-positive cells and of fibrotic tissue was measured by point-counting technique and expressed as a percentage of area. Western blot was used to determine laminin and fibronectin accumulation. The levels of messenger RNA (mRNA) for procollagen type I, fibronectin, and laminin were evaluated by Northern blot. No differences were observed in rats treated with either saline or IFN-γ alone. IFN-γ reduced HSC activation induced by liver injury, as shown by the decreased number of proliferating HSC and the reduction of parenchymal area occupied by α-SMA-positive cells observed in DMN + IFN-γ-treated animals compared with the DMN group. This was associated with reduced collagen, laminin, and fibronectin accumulation and lower levels of mRNA for procollagen type I, fibronectin, and laminin in the DMN + IFN-γ group. Thus, this study indicates that IFN-γ reduces extracellular matrix deposition in vivo by inhibition of HSC activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
Hepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
Pathogenesis of liver cirrhosis
Zhou, W.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7312 · Cited by 627
Radaeva, S., Sun, R., Jaruga, B., Nguyen, V. T., Tian, Z., & Gao, B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.055 · Cited by 610
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Shalapour, S., Lin, X.-J., Bastian, I. N., Brain, J., Burt, A. D., Aksenov, A. A., Vrbanac, A. F., Li, W., Perkins, A., Matsutani, T., et al. (2017) · Nature · doi:10.1038/nature24302 · Cited by 589
Mack, M. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.11.010 · Cited by 514
Emerging insights into Transforming growth factor Smad signal in hepatic fibrogenesis
Inagaki, Y., & Okazaki, I. (2007) · Gut · doi:10.1136/gut.2005.088690 · Cited by 464
Galli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440
Self-citationActivation of hepatic stellate cells - a key issue in liver fibrosis
Reeves, H. (2002) · Frontiers in Bioscience · doi:10.2741/reeves · Cited by 423
Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update
Elpek, G. Ö. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7260 · Cited by 382
Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases
Gao, B., Radaeva, S., & Park, O. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0309135 · Cited by 377
Cytokine mediated tissue fibrosis
Borthwick, L. A., Wynn, T. A., & Fisher, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.014 · Cited by 375
Tsukada, S., Parsons, C. J., & Rippe, R. A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.014 · Cited by 357
Svegliati-Baroni, G., Ridolfi, F., Di Sario, A., Casini, A., Marucci, L., Gaggiotti, G., Orlandoni, P., Macarri, G., Perego, L., Benedetti, A., et al. (1999) · Hepatology · doi:10.1002/hep.510290632 · Cited by 320
Self-citationFibrogenic effect of oxidative stress on rat hepatic stellate cells
Baroni, G. S., D’Ambrosio, L., Ferretti, G., Casini, A., Di Sario, A., Salzano, R., Ridolfi, F., Saccomanno, S., Jezequel, A. M., & Benedetti, A. (1998) · Hepatology · doi:10.1002/hep.510270313 · Cited by 278
Self-citationJeong, W.-I., Park, O., Radaeva, S., & Gao, B. (2006) · Hepatology · doi:10.1002/hep.21419 · Cited by 275
Wallace, K., Burt, A. D., & Wright, M. C. (2008) · Biochemical Journal · doi:10.1042/bj20071570 · Cited by 262
Weiskirchen, R., & Tacke, F. (2014) · PubMed · doi:10.3978/j.issn.2304-3881.2014.11.03 · Cited by 256
Viñas, O., Bataller, R., Sancho-Bru, P., Ginès, P., Berenguer, C., Enrich, C., Nicolás, J. M., Ercilla, G., Gallart, T., Vives, J., et al. (2003) · Hepatology · doi:10.1002/hep.1840380418 · Cited by 223
Type 3 cytokines IL-17A and IL-22 drive TGF-β–dependent liver fibrosis
Fabre, T., Molina, M. F., Soucy, G., Goulet, J.-P., Willems, B., Villeneuve, J.-P., Bilodeau, M., & Shoukry, N. H. (2018) · Science Immunology · doi:10.1126/sciimmunol.aar7754 · Cited by 155
“Type 1 inflammation, characterized by production of interleukin-1 (IL-1), IL-6, tumor necrosis factor– (TNF-), and interferon- (IFN-), is proinflammatory and correlates with liver inflammation but is antifibrogenic (3, 4).”
BackgroundWeng, H., Mertens, P. R., Gressner, A. M., & Dooley, S. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.09.014 · Cited by 152
Fabre, T., Kared, H., Friedman, S. L., & Shoukry, N. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400861 · Cited by 150
Jeong, W.-I., Park, O., Suh, Y.-G., Byun, J.-S., Park, S.-Y., Choi, E., Kim, J.-K., Ko, H., Wang, H., Miller, A. M., et al. (2011) · Hepatology · doi:10.1002/hep.24190 · Cited by 142
Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production
Di Sario, A., Bendia, E., Svegliati Baroni, G., Ridolfi, F., Casini, A., Ceni, E., Saccomanno, S., Marzioni, M., Trozzi, L., Sterpetti, P., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00245-3 · Cited by 138
Self-citationLuo, X.-Y., Takahara, T., Kawai, K., Fujino, M., Sugiyama, T., Tsuneyama, K., Tsukada, K., Nakae, S., Zhong, L., & Li, X.-K. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00193.2013 · Cited by 120
Hepatic Fibrosis, Stellate Cells, and Portal Hypertension
Rockey, D. C. (2006) · Clinics in Liver Disease · doi:10.1016/j.cld.2006.08.017 · Cited by 112
CUG-binding protein 1 regulates HSC activation and liver fibrogenesis
Wu, X., Wu, X., Ma, Y., Shao, F., Tan, Y., Tan, T., Gu, L., Zhou, Y., Sun, B., Sun, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms13498 · Cited by 88
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Fuchs, S., Yusta, B., Baggio, L. L., Varin, E. M., Matthews, D., & Drucker, D. J. (2020) · JCI Insight · doi:10.1172/jci.insight.136907 · Cited by 29
Jiang, X., Peng, Y., Liu, L., Wang, Y., Li, M., Li, W., Huang, F., Zheng, C., Xu, F., Hu, Q., et al. (2022) · Liver International · doi:10.1111/liv.15445 · Cited by 12
Qu, Y., Wu, L., Wang, Y., Peng, F., Zhang, J., Pan, D., Wang, T., Zhou, Y., Xia, J., He, J., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.041
Metadata
- Authors
- Baroni, G. S., D’Ambrosio, L., Curto, P., Casini, A., Mancini, R., Jezequel, A. M., & Benedetti, A.
- Venue
- Hepatology
- Published
- 1996-05
- Volume
- 23
- Issue
- 5
- Pages
- 1189-1199
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1983541098
- Cited by
- 295
- References
- 0
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.